Global News

Domain Therapeutics launches Kaldi Pharma

Wednesday, March 4, 2015 01:21 PM

Domain Therapeutics, a France-based biopharmaceutical company specializing in the research and early development of new drug candidates targeting G protein-coupled receptors (GPCRs), has created a Specific Purpose Vehicle (SPV), Kaldi Pharma, for the exclusive development of its A2a/A1 and A2a antagonist programs.

More... »

Quest Diagnostics

Exostar, DocuSign partner

Wednesday, March 4, 2015 01:19 PM

DocuSign, a San Francisco- and Seattle-based company that provides electronic signature technology and Digital Transaction Management (DTM) services, and Herndon, Va.-based Exostar, an information technology company offering cloud-based solutions enabling secure business-to-business collaboration, will partner to allow life sciences and healthcare organizations to automate manual, paper-based processes with faster, more secure and fully-compliant all-digital document workflows.

More... »


Sun Pharma to buy GSK’s Opiates business in Australia

Wednesday, March 4, 2015 01:16 PM

GlaxoSmithKline has reached an agreement with India-based Sun Pharma to sell GSK’s opiates business in Australia, including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) and its portfolio of opiates products along with inventory, to a subsidiary of Sun Pharma.

More... »

AtheroNova and subsidiary file for Ch. 11 bankruptcy protection

Wednesday, March 4, 2015 01:16 PM

AtheroNova and its subsidiary, AtheroNova Operations, filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court, Central District of California, Santa Ana division on March 2. The company's Chapter 11 cases are expected to be jointly administered.

More... »

Denovo Biopharma licenses late-stage neuroscience drug from Eli Lilly

Wednesday, March 4, 2015 01:15 PM

Denovo Biopharma, a privately held biotechnology company based in San Diego, has exclusively licensed Pomaglumetad Methionil (mGlu2/3 receptor agonist), a late-stage neuroscience drug, from Eli Lilly. Denovo gains all rights to develop, manufacture and commercialize pomaglumetad globally, including transfer of all intellectual property and other rights, data and information. Lilly has an option to re-acquire pomaglumetad upon a successful clinical trial, for predetermined undisclosed financial terms.

More... »

Kite Pharma expands R&D collaboration with National Cancer Institute

Wednesday, March 4, 2015 01:11 PM

Kite Pharma, a clinical stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer based in Santa Monica, Calif., has amended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).

More... »

Array BioPharma purchases phase III assets from Novartis

Wednesday, March 4, 2015 01:07 PM

Array BioPharma has completed both the binimetinib and encorafenib definitive agreements with Novartis. Along with global ownership of both assets, Array will receive an upfront payment of $85 million from Novartis.

More... »

Bristol-Myers Squibb, Bavarian Nordic ink agreement for PROSTVAC

Wednesday, March 4, 2015 01:06 PM

Bristol-Myers Squibb has signed an exclusive option to license and commercialize PROSTVAC, Bavarian Nordic's investigational phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

More... »

New patient contact registry for rare eosinophilic gastrointestinal diseases

Wednesday, March 4, 2015 09:01 AM

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) has launched a patient contact registry for individuals with eosinophilic gastrointestinal diseases (EGID), a group of rare diseases. The registry is located at www.rdcrn.org/CEGIR. Its purpose is to create a single, international database with information submitted by patients with EGID and their families. The database will enable CEGIR investigators to identify and recruit patients with EGID for new research studies for improving treatments and clinical care.

More... »

CRL announces planned management changes

Wednesday, March 4, 2015 08:50 AM

Massachusetts-based Charles River Laboratories International has announced planned management changes to be implemented over the course of 2015.

More... »

`

CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs